Artelo Biosciences (NASDAQ:ARTL) Earns “Buy” Rating from HC Wainwright

Artelo Biosciences (NASDAQ:ARTL)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They presently have a $5.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 362.96% from the company’s current price.

Separately, EF Hutton Acquisition Co. I upgraded shares of Artelo Biosciences to a “strong-buy” rating in a research note on Tuesday, October 1st.

Artelo Biosciences Stock Performance

NASDAQ ARTL opened at $1.08 on Wednesday. The firm has a market capitalization of $3.49 million, a P/E ratio of -0.38 and a beta of 1.35. The stock has a 50-day simple moving average of $1.16 and a two-hundred day simple moving average of $1.28. Artelo Biosciences has a fifty-two week low of $1.00 and a fifty-two week high of $1.75.

Artelo Biosciences (NASDAQ:ARTL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.06. As a group, analysts forecast that Artelo Biosciences will post -2.41 earnings per share for the current year.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.